NRAS and neuroblastoma: To evaluate therapeutic windows for MEK inhibitor and SHP2 inhibitor, we treated the SK-N-AS NRAS mutant (Q61K) NB cells with increasing doses of trametinib and found that only 10 nM of trametinib was sufficient to abrogate pERK (Figure S5B), which aligned with approximately 70% of the cells being inhibited (Figure S2A).